Amprologix
Amprologix is a biotechnology company focused on developing new antibiotics to combat antimicrobial resistance. Founded in 2018 in collaboration with the University of Plymouth, it leverages artificial intelligence and deep-sea microorganism research to discover and develop novel therapeutics. The company aims to bring effective treatments for bacterial infections, including MRSA, and has a pipeline of compounds progressing through pre-clinical and clinical stages. Amprologix is committed to addressing the global threat of antibiotic resistance through innovative research, partnerships, and advancing its lead compounds like NI01.
Industries
Nr. of Employees
small (1-50)
Amprologix
Derriford Research Facility, Plymouth Science Park, Research Way, Plymouth PL6 8BU, UK
Patents
Products
Lead bactericidal peptide series (NI01 family)
A series of bactericidal peptides developed for topical, nasal and inhaled applications with demonstrated preclinical efficacy in MRSA skin infection and nasal decolonisation models; development pathway includes IND filings and Phase I/II clinical studies.
Lead bactericidal peptide series (NI01 family)
A series of bactericidal peptides developed for topical, nasal and inhaled applications with demonstrated preclinical efficacy in MRSA skin infection and nasal decolonisation models; development pathway includes IND filings and Phase I/II clinical studies.
Services
Coordination and management of outsourced preclinical studies including formulation testing, stability, safety/tolerability studies and infection-model efficacy testing.
Collaborative projects combining machine-learning discovery engines with biological validation, and partnerships with research organisations for algorithm and model development.
Coordination and management of outsourced preclinical studies including formulation testing, stability, safety/tolerability studies and infection-model efficacy testing.
Collaborative projects combining machine-learning discovery engines with biological validation, and partnerships with research organisations for algorithm and model development.
Expertise Areas
- Antimicrobial peptide therapeutics
- Antibacterial drug discovery
- Preclinical development and toxicology
- Formulation development for topical, nasal and inhaled routes
Key Technologies
- AI/machine-learning-driven discovery
- Peptide therapeutics
- Ex vivo human skin microdialysis assays
- In vivo MRSA skin infection models
News & Updates
The company is working with FRP to secure early-stage financing to support its research and development activities.
CSO Mat Upton presented new data on the efficacy of NI01 in a skin infection model at the 9th AMR conference.
The company will participate in the Investival Showcase to meet industry partners and investors.
The company has filed its first patents for novel molecular structures designed by AI for bacterial infections.
Funding awarded to support the Tobraderm project for late-preclinical testing of NI01.
CSO Mat Upton presented recent research results at the ESCMID Global 2025 congress in Vienna.
The company is working with FRP to secure early-stage financing to support its research and development activities.
CSO Mat Upton presented new data on the efficacy of NI01 in a skin infection model at the 9th AMR conference.
The company will participate in the Investival Showcase to meet industry partners and investors.
The company has filed its first patents for novel molecular structures designed by AI for bacterial infections.
Funding awarded to support the Tobraderm project for late-preclinical testing of NI01.
CSO Mat Upton presented recent research results at the ESCMID Global 2025 congress in Vienna.